At R&D Directions Insider, Michael Christel speaks with Bert Spilker, who has worked at a variety of drug companies and has written books on drug development, about mergers and acquisitions, clinical trial reform, transparency, and more. "The issue of transparency has been focused on the industry, and during the '90s and early part of this decade, the industry fought this quite strongly," Spilker says, adding that industry's position has changed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.